TheScales
09-01-2001, 07:25 PM
Hello, found the AMA very useful on this subject and it
can found on there site, which is http://www.ama-assn.org .
The current article below is a good start :
Differences Between Pick Disease and Alzheimer Disease in Clinical Appearance and Rate of Cognitive Decline
Giuliano Binetti, MD; Joseph J. Locascio, PhD; Suzanne Corkin, PhD; Jean Paul Vonsattel, MD; John H. Growdon, MD
Objectives To define the cognitive characteristics of Pick disease (PcD), and to determine which features distinguish PcD from Alzheimer disease (AD), in a cross-sectional and longitudinal study.
Methods The participants were 44 patients with PcD (10 pathologically verified), 121 patients with AD (14 pathologically verified), and 60 normal control subjects. We obtained information regarding the initial symptom of dementia from each patient's caregiver, estimated global dementia severity by the Blessed Dementia Scale and the Activities of Daily Living Scale, and assessed specific cognitive domains by administering 10 tests of memory, language, visuospatial, and reasoning abilities and selective attention.
Results Among initial symptoms reported by caregivers, personality change and language impairment were significantly more common in PcD than AD; deficits in memory were common in both groups but more prevalent in AD (P<.001). At initial cognitive testing, the scores of patients with PcD were inferior to those of normal controls on all tests, except on a measure of visuospatial function; the scores of patients with AD were inferior to those of controls on all tests. Patients with PcD were superior to patients with AD on measures of explicit memory (P<.001) and visuospatial function (P = .001) but had greater impairments on the Activities of Daily Living Scale (P<.05). During the course of illness, patients with PcD declined significantly faster than those with AD on language tests and on global measures of dementia severity (P<.05), whereas measures of explicit memory and visuospatial and reasoning abilities worsened equally in both patient groups.
Conclusions There is a characteristic cognitive profile and course of dementia in PcD. Nonetheless, cognitive test performance does not clearly distinguish PcD from AD.
Arch Neurol. 2000;57:225-232
View Full Text
Author/Article Information
From the Department of Brain and Cognitive Sciences and the Clinical Research Center, Massachusetts Institute of Technology, Cambridge (Drs Binetti, Locascio, and Corkin); Department of Neurology, Massachusetts General Hospital, Boston (Drs Binetti, Locascio, and Growdon); Department of Neuropathology, Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown (Dr Vonsattel); and the Alzheimer's Disease Research Unit, Istituto di Ricovero e Cura a Carattere Scientifico, S Giovanni di Dio, Brescia, Italy (Dr Binetti).
Reprints: John H. Growdon, MD, WACC 830, Massachusetts General Hospital, Boston, MA 02114 (e-mail: growdon@helix.mgh.harvard.edu).
Accepted for publication June 24, 1999.
This research was supported by grants AG05134 (Drs Locascio, Vonsattel, and Growdon) and AG06605 (Dr Corkin) from the National Institutes of Health, Bethesda, Md, and by a grant from the Sacro Cuore Fatebenefratelli Institute, Brescia, Italy (Dr Binetti). The Massachusetts Institute of Technology Clinical Research Center, Cambridge, Mass, is supported by National Institutes of Health grant RR 00088. The Older Americans Independence Center of the Harvard Medical School Division on Aging, Boston, Mass, is supported by National Institutes of Health grant AG08812.
Take Care and GoodLuck,
TheScales !!!!
can found on there site, which is http://www.ama-assn.org .
The current article below is a good start :
Differences Between Pick Disease and Alzheimer Disease in Clinical Appearance and Rate of Cognitive Decline
Giuliano Binetti, MD; Joseph J. Locascio, PhD; Suzanne Corkin, PhD; Jean Paul Vonsattel, MD; John H. Growdon, MD
Objectives To define the cognitive characteristics of Pick disease (PcD), and to determine which features distinguish PcD from Alzheimer disease (AD), in a cross-sectional and longitudinal study.
Methods The participants were 44 patients with PcD (10 pathologically verified), 121 patients with AD (14 pathologically verified), and 60 normal control subjects. We obtained information regarding the initial symptom of dementia from each patient's caregiver, estimated global dementia severity by the Blessed Dementia Scale and the Activities of Daily Living Scale, and assessed specific cognitive domains by administering 10 tests of memory, language, visuospatial, and reasoning abilities and selective attention.
Results Among initial symptoms reported by caregivers, personality change and language impairment were significantly more common in PcD than AD; deficits in memory were common in both groups but more prevalent in AD (P<.001). At initial cognitive testing, the scores of patients with PcD were inferior to those of normal controls on all tests, except on a measure of visuospatial function; the scores of patients with AD were inferior to those of controls on all tests. Patients with PcD were superior to patients with AD on measures of explicit memory (P<.001) and visuospatial function (P = .001) but had greater impairments on the Activities of Daily Living Scale (P<.05). During the course of illness, patients with PcD declined significantly faster than those with AD on language tests and on global measures of dementia severity (P<.05), whereas measures of explicit memory and visuospatial and reasoning abilities worsened equally in both patient groups.
Conclusions There is a characteristic cognitive profile and course of dementia in PcD. Nonetheless, cognitive test performance does not clearly distinguish PcD from AD.
Arch Neurol. 2000;57:225-232
View Full Text
Author/Article Information
From the Department of Brain and Cognitive Sciences and the Clinical Research Center, Massachusetts Institute of Technology, Cambridge (Drs Binetti, Locascio, and Corkin); Department of Neurology, Massachusetts General Hospital, Boston (Drs Binetti, Locascio, and Growdon); Department of Neuropathology, Laboratory for Molecular Neuropathology, Massachusetts General Hospital, Charlestown (Dr Vonsattel); and the Alzheimer's Disease Research Unit, Istituto di Ricovero e Cura a Carattere Scientifico, S Giovanni di Dio, Brescia, Italy (Dr Binetti).
Reprints: John H. Growdon, MD, WACC 830, Massachusetts General Hospital, Boston, MA 02114 (e-mail: growdon@helix.mgh.harvard.edu).
Accepted for publication June 24, 1999.
This research was supported by grants AG05134 (Drs Locascio, Vonsattel, and Growdon) and AG06605 (Dr Corkin) from the National Institutes of Health, Bethesda, Md, and by a grant from the Sacro Cuore Fatebenefratelli Institute, Brescia, Italy (Dr Binetti). The Massachusetts Institute of Technology Clinical Research Center, Cambridge, Mass, is supported by National Institutes of Health grant RR 00088. The Older Americans Independence Center of the Harvard Medical School Division on Aging, Boston, Mass, is supported by National Institutes of Health grant AG08812.
Take Care and GoodLuck,
TheScales !!!!